NCT02329860View on ClinicalTrials.gov

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 26, 2014

Primary Completion Date

December 15, 2017

Study Completion Date

August 14, 2019

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Apatinib

DRUG

Placebo

Trial Locations (1)

222047

Jiangsu hengrui medicine CO. LTD, Lianyungang

All Listed Sponsors
collaborator

NanJing PLA 81 Hospital

OTHER

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02329860 - Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | Biotech Hunter | Biotech Hunter